Evidence review: Open Peptide Project (verified against primary PubMed, ClinicalTrials.gov & FDA records) · Last checked 2026-10-26. ← Back to Evidence Library
Argireline (acetyl hexapeptide-3/-8): what the evidence says
At a glance
What it is: a 6-amino-acid peptide (Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2) copied from the SNAP-25 protein, used in "Botox-like" skin creams. INCI names: acetyl hexapeptide-3 or acetyl hexapeptide-8. R1, R2
What the evidence says: in small trials, creams reduced wrinkle depth or roughness over 4 weeks; one 60-person placebo-controlled trial found 48.9% global improvement vs 0% with placebo. R1, R2 Much weaker than botulinum toxin. R1
Biggest risks: few for creams at cosmetic strength. Injecting it is not studied and has caused a serious mycobacterial infection. R3, R4
Rating
| Human Human evidence | Limited for topical wrinkle reduction (small RCTs) R2, R1 · Very limited for blepharospasm (24-patient pilot) R5 · No data for injection |
| Animal Animal / lab evidence | Blocks nerve signaling in cells; skin-penetration studies R1, R6 |
| Regulatory | Cosmetic ingredient, not an approved drug · 503B Category 3 (acetyl hexapeptide-3); not on the 503A list · WADA: not named R7, R8 |
| Established human dose | None as a drug. Cosmetic safety limit in Study details. Study details lists what studies used |
Evidence verdict: Wrinkle cream (topical): Limited (small placebo-controlled trials) · Injection: No supporting data, infection case report
This page reports what studies used. It is not dosing advice.
Legend: HUMAN data · ANIMAL / LAB data · UNKNOWN · UNVERIFIED: not yet confirmed against a primary source
About the evidence: the first paper came from the ingredient's developer; independent trials are small and short. A 2025 cosmetic safety panel set its limit. R1, R2, R3
What is it?
Argireline interferes with the SNARE protein complex nerves use to release signals, the same pathway botulinum toxin blocks, but far more weakly. R1, R2 Related pages: SNAP-8, Matrixyl, GHK-Cu.
Does it work?
- Human Chinese RCT (2013): 60 people, argireline:placebo 3:1, applied around the eyes for 4 weeks; 48.9% vs 0% global improvement; skin roughness fell. R2
- Human Developer study (2002): a topical emulsion cut wrinkle depth up to 30% in 30 days in healthy women (see Study details for concentration). R1
- Human Blepharospasm pilot: 24 patients on botulinum toxin; trend to longer benefit (3.7 vs 3.0 months), not conclusive. R5
- Animal Little peptide passed beyond the outer skin layer in lab skin models. R6
Is it safe?
- Human No significant adverse events in the blepharospasm pilot. R5
- Human Cosmetic safety panel (2025): safe at current low cosmetic concentrations (limit in Study details); data insufficient above that limit. R3
- Human Injection case: a 45-year-old woman developed abscesses from Mycobacterium abscessus after argireline injections in the forehead and temples, needing 5 months of antibiotics. R4
Gray-market "research use only" argireline: extra risks
A gray-market vial has no quality control and no guarantee of identity, strength or sterility. We test retail vials blind under the Open Peptide Standard; see /tests/. A passing test covers one batch on one date and does not mean the compound is safe. Injectable vials are an off-label use with no trial data. R4
What we don't know
- Unknown Whether creams work as well in larger independent trials
- Unknown Any safety data for injection
Is it legal?
- US (FDA): sold as a cosmetic ingredient; not an approved drug. On the 503B list, Acetyl Hexapeptide-3 is Category 3 (nominated without adequate support); it is not on the 503A list or FDA's safety-risk page. R7, R8, R9
- Athletes: not named on the WADA 2026 list. UNVERIFIED whether S0 could apply to injected use.
Study details
Study details
These are amounts researchers used, not recommendations.
| Study | People / model | Route | Amount used | Follow-up | Reported | Citation |
|---|---|---|---|---|---|---|
| Blanes-Mira 2002 | Healthy women | Topical | 10% oil/water emulsion | 30 days | Wrinkle depth up to −30% | PMID 18498523 |
| Wang 2013 | 60 Chinese adults | Topical, twice daily | UNVERIFIED concentration not in abstract | 4 weeks | 48.9% vs 0% improved | PMID 23417317 |
| CIR Expert Panel 2025 | Cosmetic use review | Topical | Safe up to 0.005%; insufficient data above | n/a | Safety limit | PMID 40673537 |
| Lungu 2013 | 24 patients with blepharospasm | Topical, twice daily | 0.005% emulsion | Months | Non-significant trend | PMID 23146065 |
Full reference list (PubMed, CT.gov, FDA and WADA checked Oct 26, 2026)
- R1 Blanes-Mira C, et al. Int J Cosmet Sci. 2002. PMID 18498523
- R2 Wang Y, et al. Am J Clin Dermatol. 2013. PMID 23417317
- R3 Johnson W Jr, et al. Int J Toxicol. 2025. PMID 40673537
- R4 Chen CF, et al. World J Clin Cases. 2021. PMID 33748252
- R5 Lungu C, et al. Eur J Neurol. 2013. PMID 23146065
- R6 Kraeling ME, et al. Cutan Ocul Toxicol. 2015. PMID 24754410
- R7 FDA, 503B bulk drug substances categories list (updated Mar 21, 2025). https://www.fda.gov/media/94164/download
- R8 FDA, 503A bulk drug substances categories list (updated May 14, 2026). https://www.fda.gov/media/94155/download
- R9 FDA, Certain bulk drug substances for use in compounding that may present significant safety risks (content current Apr 22, 2026). https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
Disclaimer
This page is for education and harm reduction, not medical advice or a recommendation to use Argireline (acetyl hexapeptide-3/-8). Talk to a dermatologist you trust, especially before injecting anything into the face. Report problems to FDA MedWatch (https://www.fda.gov/safety/medwatch).